CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the company will host a conference call and live webcast on Thursday, May 5, 2022, at 8:00 a.m. ET to report its first quarter 2022 financial results and other business highlights.
A live webcast can be accessed under “Events & Presentations” in the Investors section of the company’s website at
www.agios.com
. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 5738266. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.
About
Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for genetically defined diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company’s leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with active and planned programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and an industry-leading research team with unmatched expertise in cellular metabolism and genetics. For more information, please visit the company’s website at
www.agios.com
Contacts Investors:
Holly Manning, 617-844-6630
Senior Director, Investor Relations
[email protected]
Media:
Jessica Rennekamp, 857-209-3286
Director, Corporate Communications
[email protected]
Source: Agios Pharmaceuticals, Inc.
